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PENGHASILAN UJIAN ANTIBODI BERASASKAN PEPTIDA UNTUK 
MENGESAN VIRUS CHIKUNGUNYA (CHIKV) 
ABSTRAK 
Virus Chikungunya (CHIKV) yang pertama kali telah dilaporkan pada tahun 1953 
di Tanzania telah muncul semula selepas tahun 2006 dalam magnitud yang tinggi di negara 
tropika dan juga negara bukan tropika. Jangkitan CHIKV boleh menyebabkan deman 
panas dan artritis yang berpanjangan. Persamaan wujud dalam manifestasi klinikal dan 
taburan geografi dengan demam Denggi. Kit pengesanan yang boleh membezakan virus ini 
amat penting untuk mengelakkan kesilapan dalam diagnosis dan dapat menyediakan 
rawatan perubatan yang effektif kepada pesakit. Kaedah pengesanan yang sedia ada 
sebelum ini termasuk pengkulturan dan pengekstrakan virus yang prosesnya memakan 
masa, tindak balas berantai polymerase (PCR) yang memerlukan teknologi pada kadar 
yang mahal dan ujian serologi mensasarkan antibody badan yang kurang sensitif. Kajian 
ini dilaksanakan untuk membangunkan satu sistem pengesanan virus CHIKV yang mudah 
dan berkesan untuk pengesanan pada tahap akut dengan mensasarkan glikoprotein virus 
yang terdedah di permukaan. Gen yang mengekodkan glikoprotein E2 virus yang terletak 
pada permukaan virus dan mandatori untuk pengenalan reseptor, telah diklonkan dan 
diekspreskan dalam sistem E. coli. Walau bagaimanapun, protein rekombinan ini adalah 
tak larut. Pengoptimuman lanjut dalam keadaan ekspresi dan pertukaran vektor ekspresi 
tidak meningkatkan kelarutan. Oleh itu, pembinaan E2 tanpa bahagian hidrofobik pada 
terminus-C telah dilakukan. Namun, rangkuman protein yang masih juga tidak larut 
dihasilkan. Rangkuman protein yang tak larut ini telah dilarutkan dengan urea, selepas itu, 
dilipat semula dan ditulenkan. Akan tetapi, hasil dan ketulenan protein ini adalah tidak 
xviii 
 
memuaskan. Disebabkan penyediaan glikoprotein yang larut dan tulen adalah rumit, 
fragmen peptida yang pendek dan senang disintesiskan telah digunakan untuk 
menghasilkan antibodi poliklon anti-CHIKV yang monokhusus. Daripada menjalankan 
pemetaan urutan epitop melalui eksperimen makmal basah yang berulang-ulangan, penentu 
antigen yang berpotensi telah diramal mengguna analisis bioinformatik epitop selanjar dan 
tidak selanjar. Analisis epitop tidak selanjar yang membuat ramalan berdasarkan struktur 
protein 3D adalah lebih dibolehpercayai berbanding dengan analisis selanjar. Akhirnya, 8 
peptida antigenik telah dikenalpasti melalui kaedah hibrid dan konsensus. Peptida yang 
anggaran ketulenannya 85% telah disintesis secara kimia untuk pengimunan arnab putih. 
Antiserum yang dihasilkan daripada arnab ditulenkan menggunakan kromatografi affiniti 
peptida untuk menyediakan antibodi poliklon yang spesifik ke atas lokasi protein yang 
tertentu. Saringan afiniti pengikatan dengan glikoprotein rekombinan CHIKV 
menunjukkan bahawa antibodi yang dihasilkan oleh 2 peptida berprestasi lebih baik 
berbanding yang lain. Antibodi-antibodi ini adalah berpotensi untuk dikembangan ke 
peringkat ujian pengesanan yang lebih sensitif dan spesifik yang boleh digunakan di 
lapangan.  
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DEVELOPMENT OF PEPTIDE-BASED ANTIBODY ASSAY TO DETECT 
CHIKUNGUNYA VIRUS (CHIKV) 
ABSTRACT 
Chikungunya virus (CHIKV), first reported in 1953 in Tanzania, had reemerged in 
high magnitude after 2006 in tropical countries as well as spread into non-tropical regions. 
Chikungunya virus infection can cause viral fever with a side effect of severe and 
prolonged arthritis. Due to its similar clinical manifestation and geographical distribution 
with Dengue fever, a rapid detection kit to differentiate them is important to prevent 
misdiagnosis and provide effective medical care to the patient. Existing detection methods 
include time-consuming virus culturing and isolation, expensive technology requiring 
polymerase chain reaction (PCR) and less sensitive antibody targeting serological tests. 
This study was carried out to develop a simple and effective virus detection assay at the 
acute stage by targeting the surface exposed viral glycoprotein. The gene encoding E2, 
which is the glycoprotein that positioned on the viral spike and mandatory in receptor 
recognition, was cloned and expressed in E. coli system. However, the recombinant protein 
was insoluble. Further optimization on expression conditions and change of expression 
vector was not helpful either. Therefore, truncated E2 protein without hydrophobic C-
terminal was constructed. However, it was also produced insoluble inclusion body. The 
inclusion body of E2 protein was solubilized with urea, then refolded and purified. 
Nevertheless, the yield and purity of the protein was not satisfying. Due to difficulty in 
preparing soluble and pure glycoprotein, the short peptide which is easy to produce with 
high purity was employed to produce mono-specific anti-CHIKV polyclonal antibodies. 
Instead of mapping the epitope sequence through laborious wet lab experiments, the 
xx 
 
potential antigenic determinants of the CHIKV glycoprotein was predicted using 
sequential and discontinuous epitope bioinformatics analysis. Discontinuous epitope 
analyses that make prediction based on 3D protein structure is more reliable compare to 
sequential analysis. Finally, 8 antigenic peptides were identified using hybrid and 
consensus methods. They were chemically synthesized with purity of at least 85% for 
immunization of white rabbits. Antisera from the rabbits were purified using peptide 
affinity chromatography to produce site specific polyclonal antibodies. Recombinant 
CHIKV glycoprotein binding affinity screening showed that antibodies against two E2 
peptides (E2_133-147 and E2_309-323) performed better than the others. These antibodies 
can potentially be developed into a highly sensitive and specific detection assay that can be 
used in the field.  
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CHAPTER 1    
 INTRODUCTION 
 
1.1 Introduction 
Chikungunya, meaning “that which bend up” in Makonde language, was first 
reported in 1953 in Tanzania. During the 1950s to 1980s, several outbreaks were reported 
in African and Asian tropical countries. After a few decades of silence, it reemerged in 
2005-2007 in India and Indian Ocean islands by infecting millions of citizens. 
Chikungunya is transmitted by mosquitoes belonging to the genus Aedes (Aedes aegypti 
and Aedes albopictus). Patients experience intermittent high fever, rashes, headache, 
vomiting, muscle pain and joint pain during the infection for one to two weeks. Some even 
develop chronic arthritis for few months or permanently.  
To date, no effective antiviral treatment or vaccine is available for Chikungunya.  
Furthermore, due to the migration of the people, mutation of the virus and global climate 
changes, the disease is no longer limited to known tropical areas. The global distribution 
map of the disease is expanding and the number of victims continues to increase.  
Clinical manifestations of Chikungunya fever are very similar to Dengue fever. 
Moreover, these diseases occur in most of the endemic areas concurrently. Due to earlier 
discovery of Dengue and lack of knowledge on Chikungunya, many cases might be 
mistakenly diagnosed solely by clinical observations. Precise detection of the virus is 
important for a physician to provide suitable treatment and execute efficient clinical 
management.  
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Chikungunya virus (CHIKV) belongs to the Alphavirus genus of the Togaviridae 
family. Clinical identification of CHIKV includes virus isolation, molecular amplification 
by polymerase chain reaction (PCR) and serological anti-Chikungunya antibody detection. 
The virus isolation is very time-consuming and requires skillful lab technicians and highly 
secured biosafety level three (BSL3) laboratories. Majority of the detection kits available 
in the market are targeting the presence of either the viral genome or anti-virus antibodies. 
These PCR kits, however, require expensive and complicated real-time PCR instruments. 
Serological diagnosis detecting the immunoglobulin G (IgG) and immunoglobulin M (IgM) 
is widely applied but is not sensitive to detect the antibodies in the early stage of infection. 
To date, no commercial kit that targets the CHIKV viral proteins is available. Because viral 
replication is accelerated at the early stage of infection, the viral proteins are abundant in 
the host cells. Therefore, early diagnosis can be conducted by targeting these antigens.  
During the replication cycle, the envelope proteins E1 and E2 are transported and 
embedded into the lipid bilayer membrane of the host cell before virus assembly and 
budding. They are exposed on the surface of the host cells, making them the most ideal 
target for detection. Antibodies raised against these envelope proteins can be used to detect 
the presence of virus.  
In this study, we developed polyclonal antibodies against the epitopes of E1 and E2 
glycoproteins. The prediction of epitope peptide sequences that were exposed on the 
surface with antigenicity and immunogenicity was performed in silico. The peptides were 
chemically synthesized and then used for the production of the anti-peptide polyclonal 
antibodies. The direct enzyme-linked immunosorbent assay (ELISA) had shown that 
antibodies against 2 peptides were the best performing. The antibodies can potentially be 
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further developed into a low cost immunochromatography test strip for rapid and early 
detection of CHIKV.   
 
 
1.2 Aims and objectives 
This project was carried out to develop an antibody assay that allows early 
detection of CHIKV during fever onset. In order to accomplish this aim, experiments to 
fulfill the following objectives were carried out:  
1. Cloning, expression and purification of CHIKV E2 envelope protein from bacterial 
system.  
2. In silico prediction on CHIKV glycoprotein epitope and chemical synthesis of the 
peptides for anti-peptide polyclonal antibody production. 
3. Assessment of anti-peptide polyclonal antibody and development of antibody assay for 
the detection of recombinant CHIKV glycoprotein.  
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CHAPTER 2    
 LITERATURE REVIEW 
 
2.1 History of Chikungunya outbreaks 
Chikungunya was first reported in Tanzania in the year 1952-1953 (Robinson, 1955; 
Ross, 1956; Powers and Logue, 2007; Seneviratne et al., 2007). The infection was reported 
as “dengue-like-illness” until the CHIKV was determined to be the true causative 
agent(Staples et al., 2009). The neighboring country, Democratic Republic of the Congo, 
detected Chikungunya for the first time in 1958 and then again in 1960 (Pastorino et al., 
2004). Chikungunya has continued to be repeatedly detected in central Africa (Central 
Africa Republic), southern Africa (Zimbawe and South Africa) and western Africa 
(Senegal and Nigeria) in the subsequent 20 years (Schuffenecker et al., 2006; Cherian et 
al., 2009).  
In 1958, it occurred in Southeast Asia for the first time in Thailand (Aikat et al., 
1964; Sudeep and Parashar, 2008). The first outbreak in India was reported in 1963 in 
Kolkata (Shah et al., 1964; Arankalle et al., 2007), followed by Chennai, Pondicherry, 
Vellore, Visakhapattanam, Rajmundry, Kakinada and Nagpur from 1964 to 1973 
(Yergolkar et al., 2006). The occurrence of Chikungunya in Indonesia was then reported in 
Kalimantan (1973), South Sumatra (1982) and Yogyakarta (1983) (Porter et al., 2004; 
Laras et al., 2005). After hundreds of thousands of cases were reported, the occurrence 
went down to none during the following decades. The first reported CHIKV outbreaks in 
global are illustrated in Figure 2.1. 
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Figure 2.1 Global Chikungunya first reported outbreaks.  
 
2.2 Reemergence of Chikungunya 
After a long period of silence, Chikungunya emerged again in the Democratic 
Republic of Congo in early 1998-2000 and Kenya in 2004 (Pastorino et al., 2004; 
Hapuarachchi et al., 2010). During 2005–2007, enormous Chikungunya epidemics had 
infected almost 255,000 people out of a total population of 777,000 in the Indian Ocean 
islands such as Comoros islands, La Réunion, Mayotte, Mauritius, Seychelles, and 
Madagascar (Seneviratne et al., 2007), as well as 1.3 million people in 13 states of India 
(Arankalle et al., 2007). Death cases (237) were reported during outbreaks in La Réunion 
(Schwartz and Albert, 2010). Although Southeast Asian countries did not experience such 
destructive epidemics, remarkable reemergence occurred in Indonesia from 2001-2003 
(Laras et al., 2005),  Malaysia in 2006 and 2007, Singapore and Thailand in 2008 
(Theamboonlers et al., 2009; Hapuarachchi et al., 2010). Moreover, co-infection of 
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Chikungunya and Dengue was reported in Africa, India, Malaysia, as well as travelers who 
have been to India and Singapore (Nayar et al., 2007; Chahar et al., 2009; Schilling et al., 
2009; Chang et al., 2010; Nkoghe et al., 2012).  
Chikungunya was assumed not to affect countries other than tropical areas, until 
hundreds of cases were reported in France (Cordel et al., 2006; Seneviratne et al., 2007) as 
well as in North Eastern Italy (Watson, 2007; Pardigon, 2009). Some Chikungunya cases 
were brought into France by the travelers returning from tourist destinations in Indian 
Ocean islands (Parola et al., 2006). With the presence of compatible vectors, especially A. 
albopictus, the infected travelers spread Chikungunya fever to their neighbourhoods and 
slowly all over the countries.  
 Other factors that contribute to the reemergence of massive Chikungunya outbreaks 
in recent years include the changing global climate and mutation of CHIKV. Climate 
affects the life cycle, distribution and transmission of arbovirus vectors to vertebrate hosts 
as well as the dispersal pattern and evolution of arboviruses (Jansen et al., 2008; Gould and 
Higgs, 2009). Climate plays a big role in spreading Chikungunya by favouring the 
breeding of mosquito vectors (A. aegypti and A. albopictus), and efficient virus 
reproduction in the mosquito (Mourya et al., 2004; Epstein, 2007; Gould and Higgs, 2009). 
Indonesian Chikungunya reemergence in 2001 to 2003 happened after increased rainfall in 
August favouring Aedes vectors (Laras et al., 2005). 
 The most significant mutation point that might contribute to the high magnitude of 
reemergence is the E1-A226V mutation. Any changes in the E1 gene, which is the 
structural gene that makes up the envelope of the virion, might influence virion assembly, 
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disassembly, interaction with  host cell receptors and membrane fusion (Schuffenecker et 
al., 2006; Tsetsarkin et al., 2007; Kumar et al., 2008). More than 90% of the isolates after 
September 2005 contain this particular mutation (Schuffenecker et al., 2006; Jaffar-
Bandjee et al., 2009; Schwartz and Albert, 2010). E1-A226V was believed to contribute to 
cholesterol independent infection of mosquito cells leading to the increased infectivity of 
vector A. albopictus (Schuffenecker et al., 2006; Tsetsarkin et al., 2007; Kumar et al., 
2008). The mutation had changed the predominant vector from A. aegypti to A. albopictus 
(De Lamballerie et al., 2008b). Therefore, areas that lack of A. aegypti but are abundant 
with A. albopictus have now become the hot spots of Chikungunya outbreaks. However, 
the latest study carried out by Tsetsarkin et al. (2011) demonstrated that cholesterol 
independency and increased A. albopictus infectivity are actually two independent 
phenotypes that are caused by the mutation.  
 
2.3 Chikungunya outbreaks in Malaysia 
 A serological survey conducted during 1965-1969 in Peninsular Malaysia 
determined that Chikungunya-specific antibodies were found in citizens aged more than 20 
years old staying in states bordering Thailand such as Perlis, Kedah and Kelantan. Based 
on the survey, Marchette et al. (1978) predicted the population of Selangor and Perak to be 
vulnerable to Chikungunya outbreaks.  
However, there are only 2 documented outbreaks of Chikungunya in Malaysia until 
2006. The first outbreak happened in Klang, Kuala Lumpur from 6 December 1998 to 28 
February 1999 and had affected 52 citizens (Lam et al., 2001; Kit, 2002). The majority of 
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these patients were adults living in areas with poor sanitation systems (Kit, 2002). The 
second outbreak reemerged in the year 2006, from 28 March to 10 April, in Bagan Panchor, 
Taiping and had affected more than 200 villagers (Kumarasamy et al., 2006; Abubakar et 
al., 2007; Soon et al., 2007). CHIKV isolates from these 2 outbreaks are closely related, 
with 99% similarity (Kumarasamy et al., 2006). They belonged to the Asian lineage, but 
are different from the Thailand, Indonesia and coinciding Indian Ocean outbreak isolates. 
Therefore, the reemergence of CHIKV is an endemic infection (Abubakar et al., 2007).  
Interestingly, infections caused by East-Central South Africa (ECSA) were also 
reported. An elderly woman from Batu Gajah, Perak and a middle-aged man from Kinta, 
Perak were infected after their discrete trips to India in August and December 2006 
respectively (Noridah et al., 2007; Soon et al., 2007). The subsequent outbreak in Kinta 
affected 35 patients who never leave Malaysia before the outbreak (Noridah et al., 2007).  
The latest outbreak occurred during 2008-2009, started from Johor state in early 
February. It was not endemic and had propagated to other states, even to Sarawak in East 
Malaysia (Chem et al., 2010; Yusof et al., 2011). The outbreak is believed to be introduced 
from Singapore and the virus isolates are highly similar to the ECSA genotype with the 
A226V mutation (Sam et al., 2009; Chem et al., 2010). The outbreaks in Malaysia which 
caused by different CHIKV genotypes suggest that the spread of CHIKV was no longer 
limited by geographical boundaries. 
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2.4 Symptoms of Chikungunya 
 Symptoms of Chikungunya fever are very similar to Dengue fever; both of them 
cause fever as high as 104 °F, rash, headache, vomiting, myalgia and arthralgia (joint pain) 
(Ligon, 2005; Sudeep and Parashar, 2008). In the laboratory setting limited situation, 
Chikungunya fever might be differentiated from Dengue fever by apparent leukocytosis 
and arthralgia/arthritis, however, incorrect classification can lead to inappropriate case 
management (Lee et al., 2012). 
Arthritis is the most significant symptom of Chikungunya and this explains its 
name which means “that which bend up” in Makonde language (Seneviratne et al., 2007). 
The viral arthritis normally recovers in a few weeks but sometimes it becomes severe and 
requires a long recovery period.  The joint pain in CHIKV fever can last for weeks or 
months depending on individual physical fitness (Seneviratne et al., 2007; Sourisseau et al., 
2007; Sudeep and Parashar, 2008). The majority of Réunion Island outbreak patients 
suffered at the chronic stage after the CHIKV infection. They experienced distal 
polyarthritis or mild monoarthritis, frequent tenosynovitides and worsening of previous 
injuries in joints and bones (Simon et al., 2011). Although there is no specific target joint, 
arthritis during Chikungunya infection commonly appears at metacarpophalangeal joints, 
wrists, elbows, knees, ankles and metatarsal joints (Franssila and Hedman, 2006). 
Moreover, 12% of patients suffered the symptoms for years or experienced destructive 
arthritis in ankles and metatarsal heads (Brighton and Simson, 1984). Interestingly, 
Chikungunya is recovered in fibroblasts from muscles, skin and joints in mouse models 
(Couderc et al., 2008a). 
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In 1963, a death case was reported in Calcutta because of co-infection with 
meningoencephalitis, haematemesis and maleana with a sudden-shock syndrome (Aikat et 
al., 1964; Sarkar et al., 1964; Sudeep and Parashar, 2008). The neurovirulence of 
Chikungunya became more common and severe in recent outbreaks in Réunion Island. 
Chikungunya might cause cell death by inducing apoptosis of immature neurons and 
necrotic process of mature neurons (Arpino et al., 2009). The probability to suffer from 
encephalitis and severe conditions is age-dependant; children and the elderly are higher 
risk populations (Couderc et al., 2008b). However, the rate of neurological manifestation 
of Chikungunya is about 1:200, which is lower than other arboviruses such as Eastern 
Equine Encephalitis (EEE) and West Nile Virus (WNV) with rates of 1:20 and 1:100, 
respectively (Arpino et al., 2009).  
 
2.5 Causative agent – Chikungunya virus  
The causative agent of Chikungunya is known as Chikungunya virus (CHIKV) and 
it belongs to the family Togaviridae, genus Alphavirus. Genetic analysis identified 3 
distinct clusters of CHIKV: West African (WA), East-Central South African (ECSA) and 
Asian (Strauss and Strauss, 1994; Seneviratne et al., 2007). The naming is based on 
geographical distribution of its first isolation and subsequent outbreaks.  On the other hand, 
dengue fever is caused by Dengue virus, which belongs to family Flaviviridae, genus 
Flavivirus, with 4 distinct serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) has been 
discovered (Bulugahapitiya et al., 2007).  
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2.5.1 Alphavirus background 
Alphavirus is a small, spherical and enveloped positive single-stranded RNA virus 
(Strauss and Strauss, 1994). Alphavirus can be divided into “Old World Alphavirus” such 
as CHIKV, O’Nyong-nyong (ONN), Semliki Forest virus (SFV), Ross River virus (RRV), 
Sindbis virus (SIN), and Barmah Forest virus (BFV); and “New World Alphavirus” which 
refer to EEE and Venezuelan Equine Encephalitis (Thammapalo et al.) (Jaffar-Bandjee et 
al., 2009). Most of the Old World Alphaviruses are related to symptoms of arthralgia while 
the New World Alphaviruses are related to encephalitis (Powers et al., 2001).  
The Alphavirus genus has 29 members and are grouped according to their antigenic 
complexes into BFV, SFV, VEE, Western equine encephalomyelitis (Sweet), Middleburg 
virus (MIDV), Ndumu virus (NDUV), recombinant or ungrouped (Strauss and Strauss, 
1994; Powers et al., 2001).  Chikungunya virus and its most closely homologous virus, 
ONN, are under the SFV group (Powers and Logue, 2007).  This group consists of 
members such as Getah virus (GETV), Mayoro virus (MAYV), Ross River virus (RRV), 
Bebaru virus (BEBV) and the SFV (Powers et al., 2001).   WEE, which has the most 
similar base ratio with CHIKV, is grouped as recombinant (Nagatomo, 1972). Newly 
isolated species Salmon Pancrease Disease virus (SPDV), Sleeping Disease virus (SDV) 
and Trocara virus (TROCV) are not yet categorized (Powers et al., 2001). 
 Alphaviruses are widely distributed and maintained in either human or primate 
cycle through transmission by the arthropod vectors (Levinson et al., 1990). Their 
distributions in different ecological environments are dependent on the availability of their 
vectors (Powers et al., 2001). Specific host-vector interactions keep the specific virus 
endemic in certain geographical areas. However, movement of the host might bring the 
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virus to new regions. Subsequent adaptation and evolution enables the virus to survive in 
diverse surroundings (Levinson et al., 1990).  
 
2.5.2 Genome organization and protein functions 
Although the clinical manifestation and epidemiology of CHIKV and dengue virus 
overlaps, the two viruses have distinct taxonomy and genome organization. About 11.8 kb 
of linear positive single-stranded RNA make up the genome of CHIKV (Powers and Logue, 
2007). Its genome is divided into 2 open reading frames (ORFs) (Sudeep and Parashar, 
2008). Whereas the approximately 11 kb single-stranded plus-sense RNA of dengue virus 
is non-segmented (Ligon, 2005; Bulugahapitiya et al., 2007). The genome composition of 
CHIKV and dengue virus is illustrated in Figure 2.2. 
 
 
Figure 2.2 Genome composition of Chikungunya virus and Dengue virus.  
  
13 
 
The 5’ region of CHIKV genome encodes the non-structural proteins nsP1, nsP2, 
nsP3 and nsP4 while the 3’ region encodes the structural proteins such as capsid (C), E1, 
E2, 6K and E3 (Powers and Logue, 2007; Pardigon, 2009). In between the ORFs is a non-
translated junction that encodes the promoter for 26S mRNA transcription (Strauss and 
Strauss, 1994). The conserved region of the 5’ and 3’ non-translated region is important for 
minus strand synthesis (Levinson et al., 1990). The 3’ NTR serves as the polymerase 
binding site and has repeated sequences with unknown function in viral replication 
(Levinson et al., 1990). On the other hand, the dengue virus genome encodes 3 structural 
proteins: capsid (C), membrane (prM) and envelope (E), and 7 non-structural proteins: 
NS1, NS2A NS2B, NS3, NS4A, NS4B and NS5 (Perera and Kuhn, 2008). The two viruses 
have no homology between their structural genes, but, the non-structural gene NS4B and 
nsP2 has significant similarity (Singhal and Bhandarkar, 2012). 
 
2.5.2.1 Non-structural proteins 
 The translated non-structural polyprotein is cleaved into individual mature proteins 
with the facilitation of the C-terminal protease domain of nsP2 (Kim et al., 2004).  The 
mature proteins and the intermediate precursors take a role in synthesis of the minus strand 
RNA genome which is a template for subsequent 26S RNA and plus strand RNA synthesis 
(Schwartz and Albert, 2010).   
NsP1 has 3 main known functions: initiate minus strand RNA synthesis, cap the 
mRNA and modulate protease activity in nsP2 (Strauss and Strauss, 1994). The study 
using the temperature sensitive mutant ts24 suggests that nsP1 is involved in promoter 
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recognition for initiation or elongation of minus strand genome template synthesis (Wang 
et al., 1991). 5’ guanosine capping of genomic and subgenomic RNA is carried out by 
guanine-7-methyltransferase and guanylyl transferase (Leung et al., 2011). The 
intermediate polyprotein containing nsP1 inhibits cleavage between nsP2 and nsP3 by 
nsP2 protease (Strauss and Strauss, 1994). 
The N-terminal domain of nsP2 consists of a nucleoside triphosphatase required in 
the capping of RNA and a helicase which is involved in unwinding the duplex strand in 
RNA replication. The C-terminus is a protease associated with transcription of 26S RNA 
(Strauss and Strauss, 1994; Merits et al., 2001; Kim et al., 2004). Two conserved residues, 
Cys-481 and His-558, make up the catalytic dyad of the papain-like-protease (Vasiljeva et 
al., 2001). Deletion of 200 residues in the C-terminus can inhibit the protease activity, 
suggesting that this region is playing similar role like that of NS2B to the NS3 protease of 
Dengue virus (Pastorino et al., 2008).    
The crystal structure of nsP3 shows that the N-terminal has an ADP-ribose 
phosphatase domain (Malet et al., 2009). NsP3 is highly conserved at the N-terminus but 
can tolerate large deletions of the C-terminus (Strauss and Strauss, 1994). This highly 
phosphorylated protein is speculated to actively be involved in minus strand RNA 
synthesis (Strauss and Strauss, 1994). Further studies have to be done to clarify the exact 
function of the protein.  
An opal stop codon is present after nsP3 and it enables a read-through mechanism 
to produce polyproteins, P123 instead of  P1234 (Pardigon, 2009). It is speculated that the 
transcription of more P123 leads to a rapid production of more protease to convert the 
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machinery from synthesizing the minus strand RNA to the plus strand RNA (Kim et al., 
2004).  
NsP4 is an RNA-dependent polymerase (RdRp). It has a short half-life and is 
rapidly degraded because of degradation by the N-end rule pathway to regulate its amount 
(Strauss and Strauss, 1994). Ninety eight residues of its C-terminus forms the polymerase 
core catalytic domain with GDD motif, in which terminal adenylyltransferase (TATase) 
activity is also reported (Tomar et al., 2006). This activity is facilitated by host factors for 
essential RNA virus polyA-tail recovery.  
 
2.5.2.2 Structural proteins 
The capsid protein can be divided into 2 domains; N-terminal 96 residues and C-
terminal 97 residues. The N-terminal domain is non-conserved among alphaviruses, and is 
rich in proline and basic amino acids such as lysine and arginine (Strauss and Strauss, 1994; 
Wengler, 2009). The positive charges in this highly basic terminus neutralize the negative 
charges of bound RNA (Wengler, 2009). The leuzine zipper in this region assists 
nucleocapsid dimerization during viral particle assembly (Leung et al., 2011).  
In contrast, the C-terminal capsid is highly conserved, ordered in crystals and 
functions as a protease. The C-terminus folds into a trypsin-like protease structure in which 
the active site releases itself from the polyprotein precursor (Wengler, 2009). The protease 
is inactive as soon as the capsid protein is cleaved. Furthermore, the C-terminal 
hydrophobic pocket interacts with the cytoplasmic domain of the E2 glycoprotein and thus 
any movement of E2 might affect the arrangement of the nucleocapsid (Mukhopadhyay et 
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al., 2006). There is a short linker that connects the basic domain and protease domain 
(Wengler, 2009).  
E3 is a short 64 amino acid protein consisting of a β-hairpin and 3 α-helices packed 
into a horseshoe shape (Voss et al., 2010). A furin cleavage site is located at its C-terminus. 
Before cleavage by furin, E3 exists in the N-terminal of precursor p62 (or known as pE2) 
with E2 to guide translocation of p62 into the endoplasmic reticulum (ER) (Lobigs et al., 
1990). E3 in the precursor is also important to facilitate the proper conformation of E2 for 
its dimerization with E1 in the ER (Voss et al., 2010). E3 is cleaved from E2 in the post 
Golgi compartment for protein maturation and virus assembly (Lobigs et al., 1990). The 
uncleaved precursor can affect efficiency of virus production, however, virions with it 
remain capability to bind to host cells (Metz et al., 2011).  
E2 is 423 residues long while E1 is 439 residues. Both are the type I integral 
membrane proteins making up the shell enveloping the nucleocapsid (Strauss and Strauss, 
1994). The E2 protein can be divided into 4 parts: N-terminal 260 residues ectodomain, 
100 residues of stem region, 30 residues of transmembrane region and 33 residues of 
cytoplasmic domain (Mukhopadhyay et al., 2006). E2 is a β protein belonging to the 
immunoglobulin superfamily with the ectodomain divided into A, B and C (Voss et al., 
2010). Domain A is folded into the center while domain B is exposed at the membrane 
distal end. Domain C is near the anchorage base to the viral membrane. The ectodomain 
and stem region are anchored to the lipid bilayer membrane by a transmembrane helix 
which is highly hydrophobic and palmitoylated (Strauss and Strauss, 1994; Mukhopadhyay 
et al., 2006). The C-terminal cytoplasmic domain has Tyr-X-Leu and palmitoylated Cys in 
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the endodomain for interaction with core proteins in the budding process (Strauss and 
Strauss, 1994; Leung et al., 2011).  
The long thin leaf-shaped E2 with its position on the top of E1 indicates that it 
might be the first viral protein that makes contact with the host cell (Mukhopadhyay et al., 
2006).  Therefore the most significant function of the E2 protein is to interact with host cell 
surface receptor. Receptor binding is probably in the leaf-like domain at the top of spike. 
The E2 protein contains the virulence determinants and is involved in the mosquito vector 
susceptibility range (Voss et al., 2010) . Thus, E2 has most of the neutralizing epitopes on 
it (Powers et al., 2001). Studies on E2 of various alphaviruses showed residues such as 
180-220 of SIN as well as 216 and 218 of RRV are possible neutralizing epitopes 
(Mukhopadhyay et al., 2006).  
The P62-E1 heterodimer is long and twisted (150 Å long, 50 Å wide and 25 Å thick) 
(Voss et al., 2010). After furin maturation, E1 and E2 form a stable E1-E2 heterodimer 
which is transported to the plasma membrane. Three heterodimers twisted counter 
clockwise around each other are maintained by E1-E1 interaction to form one unit of the 
spike (Strauss and Strauss, 1994). The trimers are positioned at quasi-3-fold axes to form 
the virus surface lattice, and 80 units of the spike make up the virus envelope surface 
(Mukhopadhyay et al., 2006). 
The E1 protein is more conserved than E2, therefore has cross-reactive epitopes 
with other alphaviruses (Powers et al., 2001). It takes an active role in pH-dependent 
fusion with endosomal membranes (Mukhopadhyay et al., 2006). The E1 ectodomain 
consists of three domains named domain I, II and III, which are mainly composed of β-
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sheets (Voss et al., 2010). The N-terminus sequence consists of domain I followed by 
domain II, while the C-terminus consists of domain III. The secondary structure shows that 
domain I is folded into the middle of domain II and III (Mukhopadhyay et al., 2006). E1 
forms the base of the spike with domain III adjacent to the membrane while domain I and 
II pose away from the membrane (Mukhopadhyay et al., 2006). Domain II, the 
hydrophobic residues of domain III and the polar residues of domain I interact with E2 
(Mukhopadhyay et al., 2006). E1 interacts among itself through its domain I and its 
adjacent domain II (Mukhopadhyay et al., 2006). It has a transmembrane helix near its C-
terminus to anchor the protein (Mukhopadhyay et al., 2006).  
The linker between E1 and E2 is a hydrophobic peptide, named 6k, which is a 
multifunctional integral membrane protein that may aid in polyprotein cleavage, E1 protein 
translocation, membrane permeabilization and virus budding (Welch and Sefton, 1980; 
Loewy et al., 1995; Yao et al., 1996; Melton et al., 2002; Sanz et al., 2003). 6k is cleaved 
from the PE2 precursor and E1 through signalase (Strauss and Strauss, 1994). Addition of 
residues to the protein after residue F29 can affect the efficiency of glycoprotein precursor 
cleavage (Strauss and Strauss, 1994). Its C-terminus contains the translocation signal 
sequence for E1 (Strauss and Strauss, 1994). It comes to the plasma membrane along the 
spike glycoprotein complex and is speculated to be embedded into the membrane with two 
hydrophobic anti-parallel helices (Mukhopadhyay et al., 2006). Membrane permeability is 
observed 4 hours post infection (hpi), in which small molecular weight ions diffuse 
through the host membrane. This is most probably initiated by the insertion of viroporin 6k 
to form pores, whereas the function is absent if the N-terminal aromatic residues are 
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mutated (Sanz et al., 2005). The energy gradient is formed to release the mature viral 
particle into the medium (Sanz et al., 2005).   
 
2.5.3 Life cycle and replication in host cell 
The life cycles of CHIKV consist of the stages of attachment, penetration, 
disassembly, replication, assembly and release(Leung et al., 2011). It connects to the 
surface of host cells through binding with the receptor. However, the detailed identity of 
the host receptors are yet unknown. From the study in other alphaviruses, heparin sulfate, 
laminin, glycosaminoglycan, DC-SIGN, L-SIGN and integrin play important roles in this 
stage (Chevillon et al., 2008; Schwartz and Albert, 2010).  
After attachment to the host cells, the virus finds its way into the cell by 
endocytosis. Rearrangement of heterodimer E1-E2 occurs in the endosome, at acidic 
environment with pH lower than 6 (Leung et al., 2011). The E1 residues initially in contact 
with E2 move away from the spike axes, pushing E2 out from the center, exposing itself 
onto the surface and form the E1 homotrimer (Mukhopadhyay et al., 2006). The 
homotrimers then form pores in the membrane and fuse with the endosome in the presence 
of cholesterol to release the nucleocapsid into the cell cytoplasm (Chevillon et al., 2008; 
Leung et al., 2011). Protons flow from the pores into the cytoplasm, causing a regional low 
pH environment in the cytoplasm to help in the penetration of the nucleocapsid (Leung et 
al., 2011).  
Nucleocapsid uncoating occurs as soon as it is delivered into the cytoplasm within 
2 minutes (Wengler, 2009). Host factors help to prime the nucleocapsid disassembly and 
20 
 
uncoating is ceased when the 60S subunit is saturated (Wengler, 2009; Leung et al., 2011). 
Uncoating of the nucleocapsid releases the RNA genome for replication. The positive 
strand RNA resembles the mRNA and thus can be directly translated into polyprotein of 
replication complex by the host cell translation machinery. Minus strand RNA is 
synthesized as template for the 26S subgenome and 49S genome (Schwartz and Albert, 
2010). The replication and translation occurs simultaneously and is regulated by the P1234 
non-structural precursor.  
The non-structural polyprotein P1234 and nsP4 form a RNA replication complex, 
to facilitate the minus strand RNA synthesis (Chevillon et al., 2008; Leung et al., 2011). 
The polyprotein is further cleaved into intermediate complex nsP1, P23 and nsP4,  
favouring both positive and minus strand RNA genome synthesis than subgenomic 26S 
mRNA synthesis (Kim et al., 2004). An opal codon existing between the nsP3 and nsP4 
can cause high production of P123 and the absence of nsP4 (Kim et al., 2004). When the 
concentration of P123 is high, it is cleaved into individual mature proteins (Chevillon et al., 
2008).  These mature proteins amplify 26S mRNA from the minus strand RNA but do not 
synthesize this template RNA (Kim et al., 2004).  Therefore, minus strand RNA synthesis 
stops approximately 4 hpi while positive strand RNA and 26S mRNA are continuously 
being produced (Tomar et al., 2006).  
 26S mRNA, consisting of the structural polyprotein sequence, is translated into the 
precursor polyprotein C-pE2-6K-E1. The capsid protein releases itself from the precursor 
by autoproteolytic cleavage at the protease motif (Strauss and Strauss, 1994; Leung et al., 
2011). The remaining pE2-6K-E1 requires assistance from the host cell’s post-translational 
modification machinery. It is processed into pE2 and E1 in the endoplasmic reticulum and 
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the heterodimer pE2-E1 is transported towards the plasma membrane (Chevillon et al., 
2008). Finally, pE2 is cleaved into E2 and E3 at the furin cleavage site, thus the 
heterodimer E1-E2 is presented as a spike at the cell surface (Leung et al., 2011).  
 At the same time, capsid proteins in the cytoplasm assemble into the nucleocapsid, 
recognize the 5’ capped complete positive strand RNA genome and pack it into the 
icosahedral core (Leung et al., 2011). The assembled virion moves towards the plasma 
membrane and interacts with the cytoplasm domain of the E2 protein to bud off the host 
cell under the cover of the E1-E2 heterodimer glycoprotein (Wengler, 2009).  
 
Figure 2.3 The Alphavirus life cycle. (Depicted from Biology and pathogenesis of Chikungunya 
virus (Schwartz and Albert, 2010) 
22 
 
2.6 Transmission cycle and vector 
Transmission of CHIKV can be divided into sylvatic and non-sylvatic. The sylvatic 
cycle that involves non-humans is found only in West and Central Africa. The major 
species involved in sylvatic cycles are A. furcifer, A. taylori, A. luteocephalus, A. africanus, 
A. dalzieli and A. neoafricanus (Diallo et al., 1999; Powers and Logue, 2007; Sudeep and 
Parashar, 2008). Continuous drought in East Africa in 2004 might had resulted in CHIKV 
escaping from the sylvatic cycle and reemerging in Kenya as the urban cycle. (Epstein, 
2007). 
In Asia, the transmission cycle is human-mosquito-human. Mosquitoes are the 
carrier of the virus and CHIKV can persist in the vector for a long time. Humans get 
infected from mosquito bites. A. aegypti is the main vector in Asia and outbreaks during 
2004-2005 in East Africa and the Union of Comoros (Sang et al., 2008). However, the 
priority of vector in the urban cycle had experienced some changes in recent outbreaks. A. 
albopictus (tiger mosquito), formerly known as a secondary vector, has became the major 
vector instead of A. aegypti (Vazeille et al., 2007). A. albopictus originated from South 
East Asia, Western pacific and Indian Ocean Islands but its geographical distribution has 
extended west into India and African countries as well as east into the Oriental 
Indomalayan region (Knudsen, 1995; Gratz, 2004). It has also escaped from the tropical 
countries into temperate European countries and the United States (Gratz, 2004; Vazeille et 
al., 2007).  
Other than the normal transmission cycle, there is mother-to-child transmission 
reported in mothers infected near deliveries. There will be increased risk of abortion if the 
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mother is infected before the 22
nd
 week of pregnancy but the infection does not increase 
the risk of malformation (Simon et al., 2011). 
 
2.7 Treatment and antiviral strategy 
 There is currently no recognized antiviral treatment available for Chikungunya. The 
primary symptoms are reduced by analgesics (painkiller), antipyretics, chloroquine and 
anti-inflammatory agents to reduce body temperature, pain and swelling of inflammation, 
dehydration and chronic arthritis (Brighton and Simson, 1984; De Lamballerie et al., 
2008b; Sudeep and Parashar, 2008). Dengue fever patient are also given analgesics and 
antipyretics, except aspirin, sufficient fluid replacement and bed rest, to control the febrile 
sickness, with no specific antiviral treatment available (Rigau-Perez et al., 1998; 
Bulugahapitiya et al., 2007). 
 Chloroquine, discovered 40 years ago, has been used to treat Chikungunya arthritis 
because of its anti-inflammatory characteristics but not antiviral feature (De Lamballerie et 
al., 2009). Studies were unable to determine the efficacy and antiviral effect of chloroquine 
treatment. Treatment with chloroquine by 2400 mg in 5 days is globally tolerant with 
nausea and pruritis side effects (De Lamballerie et al., 2008a). However, it has 
controversial in cellulo virus replication inhibition and in vivo virus replication 
enhancement (Delogu and De Lamballerie, 2011).  
 Other than choloquine, ribavirin has been drugs common for RNA virus. However, 
resistancy of alphavirus mutant strain towards ribavirin was reported (Scheidel et al., 
1987). In spite of that, its combination with α-inteferon can enhance the performance 
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(Briolant et al., 2004). Azide molecule was capable of VEE inactivation and viral 
membrane protein inhibition with UV exposure and the 1,5 iodonapthyl azide specifically 
had been found to inhibit CHIKV replication (Sharma et al., 2012).  
Natural products are the current concern of the public, using medicinal plants for 
their antiviral properties. Several potential antiviral phytochemicals from plants have been 
studied, such as scleroglucan polysaccharides that prevent attachment of virus to 
glycoprotein of membrane, polyphenols that inhibit binding of virus to host cells and 
replication enzymes, flavonoids that inhibit polymerase, meliacine that affects virus 
disassembly and budding, Aloe polymannose that induces antibody production against non-
enveloped capsid protein, sulphated polysaccharide groups that inhibit viral adsorption 
processes and dry Gingyo-san that significantly reduces fever and suppresses interleukin-
1α (Jassim and Naji, 2003).  
In silico route had been utilized to identify CHIKV inhibitors. The study based on 
nsP2 protein had optimized a novel compound which was very impressive in inhibiting 
CHIKV replication compared to chloroquine as well as simple to be synthesized (Bassetto 
et al., 2013). Studies are ongoing to determine the accuracy of the finding on this molecule 
as candidate for clinical treatment.  
The other strategy to overcome CHIKV is by using RNA interference (RNAi) and 
antisense oligonucleotides to inhibit post-transcription of mRNA (De Lamballerie et al., 
2008b; Lakshmi et al., 2008; Sudeep and Parashar, 2008). Dash et al. (2008) found that 2 
small interfering RNAs (siRNAs) against the conserved regions in nsP3 and E1 can inhibit 
